





(A)

Before treatment





After treatment



(B)



Before treatment

After treatment



(C) Before treatment





After treatment



(D)

Before treatment




After treatment



(E)

Before treatment




After treatment



(F)

Before treatment




After treatment



(G)

Before treatment




After treatment



(H)

Before treatment





After treatment



(I)

Before treatment




After treatment



(J)

Before treatment

After treatment



Supplementary Figure 1 CT or MRI scans of ten representative patients who were treated with the combination of HAIC with TKIs and anti-PD-1 antibodies. **(A)** Patients 1 achieved partial response based on RECIST and mRECIST criteria. **(B)** Patients 2 achieved partial response based on RECIST and mRECIST criteria. **(C)** Patients 3 achieved partial response based on RECIST and mRECIST criteria. **(D)** Patients 4 achieved partial response based on RECIST and mRECIST criteria. **(E)** Patients 5 achieved partial response based on RECIST and mRECIST criteria. **(F)** Patients 6 achieved partial response based on RECIST and mRECIST criteria. **(G)** Patients 7 achieved partial response based on RECIST and mRECIST criteria. **(H)** Patients 8 achieved partial response based on RECIST and mRECIST criteria. **(I)** Patients 9 achieved partial response based on RECIST and mRECIST criteria. **(J)** Patients 10 achieved partial response based on RECIST and mRECIST criteria.

CT, Computed Tomography; MRI, Magnetic Resonance Imaging; HAIC, hepatic arterial chemotherapy; TKIs, tyrosine kinase inhibitor; RECIST, Response Evaluation Criteria in Solid Tumors; PVTT, portal vein tumor thrombus; IVCTT, inferior vena cava tumor thrombus.